2017
DOI: 10.18632/oncotarget.15504
|View full text |Cite
|
Sign up to set email alerts
|

CDKN2B gene rs1063192 polymorphism decreases the risk of glaucoma

Abstract: The aim of this meta-analysis was to evaluate the association between cyclin-dependent kinase Inhibitor-2B (CDKN2B) gene rs1063192 polymorphism and glaucoma risk. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. A total of 14 case-control studies involving 11,316 cases and 24,055 controls were included. Meta-analysis showed that CDKN2B gene rs1063192 polymorphism was associated with a decr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 33 publications
0
7
0
Order By: Relevance
“…Pooled analysis on POAG cases and controls revealed a significant association between rs1063192, rs2157719, rs4977756 and POAG except rs3217992. Another meta-analysis, conducted by Hu et al [ 47 ] in 2017 on 11,316 cases and 24,055 controls evaluated CDKN2B rs1063192 and it was found to be associated with decreased risk of glaucoma. Our findings were also in the concordance with previously done meta-analysis [ 47 ], rs1063192 was observed to be associated with POAG under fixed and random effect model with pooled OR ranging from 0.64 to 0.84 under dominant, heterozygous, recessive genetic model analysis with overall p ≤ 0.0001.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Pooled analysis on POAG cases and controls revealed a significant association between rs1063192, rs2157719, rs4977756 and POAG except rs3217992. Another meta-analysis, conducted by Hu et al [ 47 ] in 2017 on 11,316 cases and 24,055 controls evaluated CDKN2B rs1063192 and it was found to be associated with decreased risk of glaucoma. Our findings were also in the concordance with previously done meta-analysis [ 47 ], rs1063192 was observed to be associated with POAG under fixed and random effect model with pooled OR ranging from 0.64 to 0.84 under dominant, heterozygous, recessive genetic model analysis with overall p ≤ 0.0001.…”
Section: Discussionmentioning
confidence: 99%
“…Another meta-analysis, conducted by Hu et al [ 47 ] in 2017 on 11,316 cases and 24,055 controls evaluated CDKN2B rs1063192 and it was found to be associated with decreased risk of glaucoma. Our findings were also in the concordance with previously done meta-analysis [ 47 ], rs1063192 was observed to be associated with POAG under fixed and random effect model with pooled OR ranging from 0.64 to 0.84 under dominant, heterozygous, recessive genetic model analysis with overall p ≤ 0.0001. Meta-analysis of rs2147719 and rs4977756 also showed statistically significant association of these SNPs with decreased risk of POAG progression with pooled OR ranging from 0.46 to 0.77 and 0.85 to 0.90 respectively, under various genetic models.…”
Section: Discussionmentioning
confidence: 99%
“…[9,35,36] The small sample sizes, the clinical heterogeneity and the different ethnic populations seem to be the main factors contributing to the inconclusive findings of the studies. [37] A recent meta-analysis of Hu and He [37] found that rs1063192 polymorphism decreases the risk of glaucoma among Caucasians, Asians and Africans. However, the SNP of CDKN2B rs3217992 in patients with glaucoma has not been genotyped until now.…”
Section: Discussionmentioning
confidence: 99%
“…[9,35,36] Both rs3217992 and rs1063192 polymorphisms in CDKN2B gene are miRNA-binding-site variants, with the association of rs1063192 with POAG being widely studied in various ethnic groups. [30,35,37] However, the possible association between CDKN2B rs3217992 polymorphism and glaucoma risk has not been studied in any population.…”
Section: Introductionmentioning
confidence: 99%
“…The CDKN2B gene (cyclin dependent kinase inhibitor 2B) is a strong cell cycle inhibitorprotein, acting jointly with CDK4 and CDK6. It may cause the cell cycle retention effect of TGF-beta [29,30].…”
Section: Discussionmentioning
confidence: 99%